JP2024540439A - 叢状神経線維腫の治療又は予防に使用するためのニトロキソリン - Google Patents

叢状神経線維腫の治療又は予防に使用するためのニトロキソリン Download PDF

Info

Publication number
JP2024540439A
JP2024540439A JP2024527790A JP2024527790A JP2024540439A JP 2024540439 A JP2024540439 A JP 2024540439A JP 2024527790 A JP2024527790 A JP 2024527790A JP 2024527790 A JP2024527790 A JP 2024527790A JP 2024540439 A JP2024540439 A JP 2024540439A
Authority
JP
Japan
Prior art keywords
composition
nitroxoline
use according
pharma
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540439A5 (https=
JPWO2023089328A5 (https=
Inventor
ブラウン デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Healx Ltd
Original Assignee
Healx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healx Ltd filed Critical Healx Ltd
Publication of JP2024540439A publication Critical patent/JP2024540439A/ja
Publication of JP2024540439A5 publication Critical patent/JP2024540439A5/ja
Publication of JPWO2023089328A5 publication Critical patent/JPWO2023089328A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024527790A 2021-11-19 2022-11-18 叢状神経線維腫の治療又は予防に使用するためのニトロキソリン Pending JP2024540439A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2116743.2 2021-11-19
GBGB2116743.2A GB202116743D0 (en) 2021-11-19 2021-11-19 Treatment
PCT/GB2022/052933 WO2023089328A1 (en) 2021-11-19 2022-11-18 Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma

Publications (3)

Publication Number Publication Date
JP2024540439A true JP2024540439A (ja) 2024-10-31
JP2024540439A5 JP2024540439A5 (https=) 2025-11-17
JPWO2023089328A5 JPWO2023089328A5 (https=) 2025-11-17

Family

ID=79163954

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527790A Pending JP2024540439A (ja) 2021-11-19 2022-11-18 叢状神経線維腫の治療又は予防に使用するためのニトロキソリン

Country Status (11)

Country Link
US (1) US20250000852A1 (https=)
EP (1) EP4433054A1 (https=)
JP (1) JP2024540439A (https=)
KR (1) KR20240108407A (https=)
CN (1) CN118215479A (https=)
AU (1) AU2022392456A1 (https=)
CA (1) CA3238805A1 (https=)
GB (1) GB202116743D0 (https=)
IL (1) IL312885A (https=)
MX (1) MX2024006105A (https=)
WO (1) WO2023089328A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218460D0 (en) * 2022-12-08 2023-01-25 Healx Ltd Treatment
WO2026022492A1 (en) * 2024-07-26 2026-01-29 Healx Limited Nitroxoline for use in the treatment and/or prevention of pain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2641471T3 (es) * 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
GB202108224D0 (en) * 2021-06-09 2021-07-21 Healx Ltd Treatment

Also Published As

Publication number Publication date
AU2022392456A1 (en) 2024-05-23
WO2023089328A1 (en) 2023-05-25
US20250000852A1 (en) 2025-01-02
CA3238805A1 (en) 2023-05-25
MX2024006105A (es) 2024-05-30
KR20240108407A (ko) 2024-07-09
CN118215479A (zh) 2024-06-18
EP4433054A1 (en) 2024-09-25
IL312885A (en) 2024-07-01
GB202116743D0 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
HUP0302677A2 (hu) Módszer a fájdalom megszüntetésére
JP2024540439A (ja) 叢状神経線維腫の治療又は予防に使用するためのニトロキソリン
KR102766876B1 (ko) 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물
CN113194946B (zh) 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法
US20240261276A1 (en) Nitroxoline for use in the treatment of cutaneous neurofibroma
Gao et al. A novel compound ligusticum cycloprolactam alleviates neuroinflammation after ischemic stroke via the FPR1/NLRP3 signaling axis
CN115397415A (zh) 乳腺癌治疗剂
JP2013504550A (ja) 癌細胞アポトーシス
CN113329749A (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
JP2018522936A (ja) ぶどう膜黒色腫の処置のためのｍｄｍ２阻害剤
JP2008534471A (ja) 癌療法性粘膜炎の治療および予防のためのベンズアミジン誘導体
US20230255943A1 (en) Mmp-9 and mmp-12 inhibition for treating spinal cord injury or related injury to neurological tissue
CN120322233A (zh) 用于在恶性周围神经鞘瘤的治疗或预防中使用的硝羟喹啉
TW202519221A (zh) Ｗｅｅ１抑制劑及ｐｋｍｙｔ１抑制劑之組合
Nabiya et al. Identification of Fungal Bioactive Compounds Targeting MMP-9 for Endometriosis-An In silico Approach
WO2023202439A1 (zh) 二萜化合物衍生物或其盐在制备防治特应性皮炎的药物中的应用
WO2026065490A1 (zh) Mitoxantrone在制备药物中的用途、治疗或预防神经内分泌肿瘤的方法
WO2026065486A1 (zh) Quisinostat在制备药物中的用途、治疗或预防神经内分泌肿瘤的方法
CN113876780A (zh) 一种药物组合物及其在制备治疗非小细胞肺癌的药物方面的应用
CN116327772A (zh) SMO抑制剂Sonidegib对管腔型乳腺癌骨转移的靶向治疗方法
CN120302974A (zh) 喹诺林化合物治疗甲状腺癌的用途
CN115778962A (zh) 治疗男性食管癌患者的药物及其相关应用
KR101693186B1 (ko) ＰＡＮ-ＥｒｂＢ 억제제의 암 치료 효과 예측에 관한 정보 제공 방법
KR20210013573A (ko) 파라세타몰: 아미트리프틸린의 고정 용량 조성물 및 혼합 암 통증의 치료방법
NZ716668B2 (en) Cancer treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251106